Cancer in patients on Dapagliflozin and other antidiabetic treatment

Study identifier:D1690R00007

ClinicalTrials.gov identifier:NCT02695121

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1125000

Study type

Observational

Age

N/A

Date

Study Start Date: 01 Jan 2017
Estimated Primary Completion Date: 31 Dec 2024
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria